CSIMarket
 


Fate Therapeutics Inc   (FATE)
Other Ticker:  
 

Fate Therapeutics Inc 's Quick Ratio

FATE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.81 below Fate Therapeutics Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 103 other companies have achieved higher Quick Ratio than Fate Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1212 to 1294.

Explain Quick Ratio?
How much Cash & cash equivalents FATE´s has?
What are FATE´s Current Liabilities?


FATE Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -60.23 % -51.17 % -37.56 % 40.31 % 13.12 %
Y / Y Cash & cash equivalent Change -59.39 % -15.33 % -35.1 % 226.56 % -36.45 %
Quick Ratio MRQ 0.81 1.05 0.86 3.82 0.79
FATE's Total Ranking # 1294 # 1212 # 1780 # 347 # 2250
Seq. Current Liabilities Change -7.51 % -8.14 % -57.34 % 9.73 % 13.57 %
Seq. Cash & cash equivalent Change -28.78 % 11.38 % -90.37 % 431.38 % 48.52 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 104
Healthcare Sector # 475
Overall Market # 1294


Quick Ratio Statistics
High Average Low
11.81 4.98 0.6
(Sep 30 2014)   (Jun 30 2022)




Financial Statements
Fate Therapeutics Inc 's Current Liabilities $ 41 Millions Visit FATE's Balance sheet
Fate Therapeutics Inc 's Cash & cash equivalent $ 33 Millions Visit FATE's Balance sheet
Source of FATE's Sales Visit FATE's Sales by Geography


Cumulative Fate Therapeutics Inc 's Quick Ratio

FATE's Quick Ratio for the trailling 12 Months

FATE Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -60.23 % -51.17 % -37.56 % 40.31 % 13.12 %
Y / Y Cash & cash equivalent TTM Growth -59.39 % -15.33 % -35.1 % 226.56 % -36.45 %
Quick Ratio TTM 2.24 1.95 1.72 1.65 0.95
Total Ranking TTM # 905 # 1056 # 1248 # 1524 # 2067
Seq. Current Liabilities TTM Growth -7.51 % -8.14 % -57.34 % 9.73 % 13.57 %
Seq. Cash & cash equivalent TTM Growth -28.78 % 11.38 % -90.37 % 431.38 % 48.52 %


On the trailing twelve months basis Current Liabilities decreased faster than Fate Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Fate Therapeutics Inc 's Quick Ratio to 2.24, Quick Ratio remained below FATE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 164 other companies have achieved higher Quick Ratio than Fate Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1447 to 1534.

Explain Quick Ratio?
How much Cash & cash equivalents FATE´s has?
What are FATE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 165
Healthcare Sector # 1001
Within the Market # 1294


trailing twelve months Quick Ratio Statistics
High Average Low
6.34 3.92 0.95
(Sep 30 2020)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Adaptimmune Therapeutics Plc  2.15 $ 161.728  Millions$ 75.146  Millions
Immunitybio inc   2.10 $ 189.796  Millions$ 90.324  Millions
Amgen Inc   2.05 $ 34,741.000  Millions$ 16,954.000  Millions
C4 Therapeutics Inc   2.01 $ 60.971  Millions$ 30.271  Millions
Adma Biologics Inc   1.82 $ 74.157  Millions$ 40.715  Millions
Vaxart Inc   1.76 $ 19.799  Millions$ 11.268  Millions
Biomx Inc   1.76 $ 22.450  Millions$ 12.784  Millions
Repligen Corp  1.75 $ 630.779  Millions$ 360.049  Millions
Moderna Inc   1.73 $ 7,573.000  Millions$ 4,385.000  Millions
Eiger Biopharmaceuticals Inc   1.69 $ 27.501  Millions$ 16.319  Millions
Neurocrine Biosciences Inc   1.58 $ 1,095.100  Millions$ 691.600  Millions
Qiagen N v   1.57 $ 1,057.782  Millions$ 672.125  Millions
Lexeo Therapeutics Inc   1.54 $ 35.449  Millions$ 23.035  Millions
Cargo Therapeutics Inc   1.47 $ 60.344  Millions$ 41.134  Millions
Aptose Biosciences Inc   1.43 $ 17.717  Millions$ 12.380  Millions
Ladrx Corporation  1.40 $ 2.933  Millions$ 2.100  Millions
Cidara Therapeutics Inc   1.37 $ 48.670  Millions$ 35.620  Millions
Seagen Inc   1.30 $ 1,236.986  Millions$ 954.716  Millions
Atara Biotherapeutics Inc   1.29 $ 102.408  Millions$ 79.089  Millions
Estrella Immunopharma Inc   1.28 $ 22.138  Millions$ 17.281  Millions
Pluri Inc   1.22 $ 5.253  Millions$ 4.322  Millions
Nanostring Technologies Inc   1.21 $ 94.098  Millions$ 77.532  Millions
Sangamo Therapeutics Inc   1.17 $ 56.514  Millions$ 48.482  Millions
Bio techne Corp  1.16 $ 148.663  Millions$ 127.754  Millions
Sqz Biotechnologies Company  1.15 $ 10.193  Millions$ 8.832  Millions
Bluebird Bio Inc   1.10 $ 174.293  Millions$ 158.957  Millions
Meiragtx Holdings Plc  1.00 $ 63.365  Millions$ 63.514  Millions
Calidi Biotherapeutics Inc   0.93 $ 10.147  Millions$ 10.873  Millions
Taysha Gene Therapies Inc   0.91 $ 164.278  Millions$ 180.451  Millions
Tarsus Pharmaceuticals Inc   0.87 $ 20.213  Millions$ 23.249  Millions

Date modified: 2023-11-10T01:06:15+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com